Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03828019 · ClinicalTrials.gov registry record · Phase 3
Adalimumab vs. Conventional Immunosuppression for Uveitis Trial
A Phase 3 study, sponsored by JHSPH Center for Clinical Trials.
- Completed
- Registry status
- Phase 3
- Development phase
- 227
- Enrollment target
NCT03828019 is a Phase 3 study that has completed, run by JHSPH Center for Clinical Trials. The registered enrollment target is 227 participants.
The verdict
NCT03828019, a Phase 3 study, has completed, sponsored by JHSPH Center for Clinical Trials.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 227 participants
- Enrollment target
Study Summary
Non-infectious intermediate, posterior, and panuveitides are chronic, potentially-blinding diseases. Vision-threatening cases require long-term therapy with oral corticosteroids and immunosuppression. Based upon preliminary data, adalimumab, a fully-human, anti-tumor necrosis(TNF)-α monoclonal antibody, now US FDA-approved for uveitis treatment, may be a superior corticosteroid-sparing agent than conventional immunosuppressive drugs. The ADVISE Trial is multicenter randomized, parallel-treatment, comparative effectiveness trial comparing adalimumab to conventional (small molecule) immunosuppression for corticosteroid spring in the treatment of non-infectious, intermediate, posterior, and panuveitides.
Interventions
- BIOLOGICAL Adalimumab (ADA)
- DRUG Conventional immunosuppression (CON)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 227 participants |
| Start Date | 2019-09-16 |
| Est. Completion | 2024-09-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03828019
The ClinicalTrials.gov registry entry for NCT03828019 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 227 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is JHSPH Center for Clinical Trials, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Adalimumab (ADA) is the first listed.
NCT03828019 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03828019 about?
NCT03828019 is a clinical study titled "Adalimumab vs. Conventional Immunosuppression for Uveitis Trial". Non-infectious intermediate, posterior, and panuveitides are chronic, potentially-blinding diseases. Vision-threatening cases require long-term therapy with oral corticosteroids and immunosuppression. Based upon preliminary data, adalimumab, a fully-human, anti-tumor necrosis(TNF)-α monoclonal antib...
What is the current status of trial NCT03828019?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 227 participants. The study started on 2019-09-16. Estimated completion is 2024-09-09.
What interventions are being tested in trial NCT03828019?
The interventions under investigation include: Adalimumab (ADA) (BIOLOGICAL), Conventional immunosuppression (CON) (DRUG).
Who is sponsoring clinical trial NCT03828019?
This trial is sponsored by JHSPH Center for Clinical Trials, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.